Drugplain

Esomeprazole Magnesium 20 mg/1

Esomeprazole Magnesium · CAPSULE, DELAYED RELEASE · LITTLE PHARMA, INC.

10 Recalls on Record
Plain English

Esomeprazole Magnesium is a capsule, delayed release containing esomeprazole magnesium at 20 mg/1, taken oral. Manufactured by LITTLE PHARMA, INC..

Key Facts

Brand Name
Esomeprazole Magnesium
Generic Name
Esomeprazole Magnesium
NDC Code (Product)
72559-011
Manufacturer
LITTLE PHARMA, INC.
Strength
20 mg/1
Dosage Form
CAPSULE, DELAYED RELEASE
Route
ORAL
Marketing Status
Application #
ANDA212866
Marketing Start
03/23/2021

Recall History

10 Recalls on Record
Class III06/21/2022

SUN PHARMACEUTICAL INDUSTRIES INC

Superpotent Drug: Out of specification for assay at the 12-month timepoint.

TerminatedVoluntary: Firm initiated
Class III06/21/2022

SUN PHARMACEUTICAL INDUSTRIES INC

Superpotent Drug: Out of specification for assay at the 12-month timepoint.

TerminatedVoluntary: Firm initiated
Class II12/17/2020

CIPLA

Cross- contamination with other products: The excipient, Crospovidone, NF is contaminated with theophylline

TerminatedVoluntary: Firm initiated
Class II05/13/2025

Zydus Pharmaceuticals (USA) Inc

Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation product during Related Compounds testing during long term stability.

OngoingVoluntary: Firm initiated
Class II12/17/2020

CIPLA

Cross- contamination with other products: The excipient, Crospovidone, NF is contaminated with theophylline

TerminatedVoluntary: Firm initiated
Class II06/10/2015

AstraZeneca Pharmaceuticals LP

Presence of Foreign Tablets/Capsules: Confimed customer compliant by a retail pharmacist that an unopened bottle labeled as NEXIUM¿ capsules contained 60 SEROQUEL¿ XR tablets.

TerminatedVoluntary: Firm initiated
Class II04/01/2022

Mylan Institutional, Inc. (d.b.a. UDL Laboratories)

Failed Impurities/Degradation Specifications: OOS result was obtained for Any Other Individual Impurity at the 12M room temperature time point.

TerminatedVoluntary: Firm initiated
Class III11/14/2024

Zydus Pharmaceuticals (USA) Inc

Labeling: Not Elsewhere Classified - Wrong NDC number

OngoingVoluntary: Firm initiated
Class III07/02/2012

ASTRA ZENECA Lp

Adulterated Presence of Foreign Tablets/Capsules: Some bottles may contain a small number of Nexium 20 mg capsules intended for the Japanese market in addtion to Nexium 40 mg capsules.

TerminatedVoluntary: Firm initiated
Class III04/24/2020

Dr. Reddy's Laboratories, Inc.

Discoloration: product contains brown pellets

TerminatedVoluntary: Firm initiated

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

chronic kidney disease5,025 reports
acute kidney injury4,614 reports
nausea4,128 reports
diarrhoea3,964 reports
headache3,610 reports
fatigue3,603 reports
drug ineffective3,415 reports
off label use3,367 reports
dyspnoea3,339 reports
pain2,812 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

1 INDICATIONS AND USAGE Esomeprazole magnesium delayed-release capsules are a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagn

Dosage & Administration

2 DOSAGE AND ADMINISTRATION 1 A maximum dosage of 20 mg once daily is recommended for patients with severe liver impairment (Child-Pugh Class C). 2 Controlled studies do not extend beyond 6 months. 3 Refer to the amoxicillin and clarithromycin prescribing information for dosage adjustments in elderly and renally-impaired patients. 4 A starting dosage of 20 mg twice daily is recommended for patients with severe liver impairment (Child-Pugh Class C). Population Recommended Adult ( 2.1 ) and Pediatric Dosage ( 2.2 ) Healing of EE (12 years and older) Adults 20 mg or 40 mg 1 once daily for 4 to 8 weeks; some patients may require an additional 4 to 8 weeks 12 years to 17 years 20 mg or 40 mg 1 once daily for 4 to 8 weeks Maintenance of Healing of EE Adults 20 mg once daily. Controlled studies do not extend beyond 6 months Treatment of Symptomatic GERD Adults 20 mg once daily for 4 weeks some patients may require an additional 4 weeks 12 years to 17 years 20 mg once daily for 4 weeks Risk Reduction of NSAID-Associated Gastric Ulcer Adults 20 mg or 40 mg 1 once daily for up to 6 months 2 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Adults Esomeprazole magnesium de

Contraindications

4 CONTRAINDICATIONS Esomeprazole magnesium delayed-release capsules are contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions (5.2) , Adverse Reactions (6.2) ]. For information about contraindications of amoxicillin and clarithromycin, indicated in combination with esomeprazole magnesium delayed-release capsules for H. pylori eradication to reduce the risk of duodenal ulcer recurrence, refer to the Contraindications section of the respective prescribing information. Proton pump inhibitors (PPIs), including esomeprazole magnesium delayed-release capsules, are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions (7) ] . Known hypersensitivity to substituted benzimidazoles or any component of the formulation. ( 4 ) Patients receiving rilpivirine-containing products. ( 4 , 7 ) Refer to the Contraindications section of the prescribing information for amoxicillin and clarithromycin, when administered in

Drug Interactions

7 DRUG INTERACTIONS Tables 3 and 4 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with esomeprazole and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 3: Clinically Relevant Interactions Affecting Drugs Co-Administered with Esomeprazole and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine atazanavir, and nelfinavir) when used concomitantly with esomeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology (12.3) ]. Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with esomeprazole may increase toxicity [see Clinical Pharmacology (12.3) ]. There are other antiretroviral drugs which do not result in clinically relevant interactions with esomeprazole. Intervention: Rilpivirine-cont

Adverse Reactions

6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in labeling: Acute Tubulointerstitial Nephritis [see Warnings and Precautions (5.2) ] Clostridium difficile -Associated Diarrhea [see Warnings and Precautions (5.3) ] Bone Fracture [see Warnings and Precautions (5.4) ] Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.5) ] Cutaneous and Systemic Lupus Erythematosus [see Warnings and Precautions (5.6) ] Cyanocobalamin (Vitamin B-12) Deficiency [see Warnings and Precautions (5.8) ] Hypomagnesemia and Mineral Metabolism [see Warnings and Precautions (5.9) ] Fundic Gland Polyps [see Warnings and Precautions (5.13) ] Most common adverse reactions ( 6.1 ): Adults (≥ 18 years) (≥1%) are: headache, diarrhea, nausea, flatulence, abdominal pain, constipation, and dry mouth. Pediatrics (1 to 17 years) (≥2%) are: headache, diarrhea, abdominal pain, nausea, and somnolence. To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates

Frequently Asked Questions

What is Esomeprazole Magnesium used for?

Esomeprazole Magnesium contains Esomeprazole Magnesium. It is a capsule, delayed release taken oral. Consult your doctor for specific uses.

Is Esomeprazole Magnesium a controlled substance?

Esomeprazole Magnesium is not classified as a controlled substance by the DEA.

What is the generic name for Esomeprazole Magnesium?

The generic name for Esomeprazole Magnesium is Esomeprazole Magnesium. There are 4 other brand versions of Esomeprazole Magnesium.

What is the NDC code for Esomeprazole Magnesium 20 mg/1?

The NDC (National Drug Code) for Esomeprazole Magnesium 20 mg/1 is 72559-011, listed by LITTLE PHARMA, INC..